Part of a comprehensive analysis of the Human Biomedical Research Act 2015
All Parts in This Series
Institutional Review Board Waivers under the Human Biomedical Research Act 2015: Key Provisions and Their Purpose
The Human Biomedical Research Act 2015 (HBRA) establishes a comprehensive regulatory framework for the conduct of human biomedical research in Singapore. A critical aspect of this framework is the role of the Institutional Review Board (IRB) in safeguarding the rights and welfare of research subjects and donors, particularly when research involves the use of individually-identifiable human biological material or health information. This article analyses the key provisions governing IRB waivers under the HBRA, explaining their purpose and the rationale behind each requirement.
Section 3: Conditions for Institutional Review Board Waivers
Section 3 of the HBRA sets out the specific criteria under which an IRB may grant a waiver for the use of individually-identifiable human biological material or health information without obtaining the consent of the person to whom the material or information relates. The provision reads:
"Where the institutional review board is satisfied that — (a) the research cannot reasonably be carried out without the use of the human biological material or health information in an individually‑identifiable form; (b) the process of obtaining consent from the person, to which the individually‑identifiable human biological material or health information relates, will involve a disproportionate amount of effort and resources relative to the research requirements; (c) the use of the individually‑identifiable human biological material or health information (as the case may be) involves no more than minimal risk to the research subject or donor; (d) the waiver concerned will not otherwise adversely affect the rights and welfare of the research subject or donor; and (e) the human biomedical research or health information research would reasonably be considered to contribute to the greater public good." — Section 3, Human Biomedical Research Act 2015
Verify Section 3 in source document →
This provision is foundational in balancing the facilitation of important biomedical research with the protection of individual rights. Each subsection serves a distinct purpose, which we explore below.
Subsection (a): Necessity of Using Individually-Identifiable Material
Subsection (a) requires that the IRB be satisfied that the research "cannot reasonably be carried out without the use of the human biological material or health information in an individually‑identifiable form." This criterion exists to ensure that identifiable data or materials are only used when absolutely necessary, thereby minimizing unnecessary intrusion into personal privacy.
By mandating this condition, the HBRA acknowledges the sensitivity of individually-identifiable information and restricts its use to cases where anonymized or de-identified data would be insufficient for the research objectives. This protects individuals from unwarranted exposure of their personal health information.
Subsection (b): Disproportionate Effort in Obtaining Consent
Subsection (b) permits a waiver when "the process of obtaining consent ... will involve a disproportionate amount of effort and resources relative to the research requirements." This provision recognizes practical challenges in obtaining consent, such as when subjects are numerous, untraceable, or deceased, and the research has significant potential benefits.
The rationale here is to avoid imposing unreasonable burdens on researchers that could stifle valuable research, while still maintaining ethical standards. It ensures that waivers are not granted lightly but only when the cost and effort of obtaining consent are disproportionate to the research's scope and impact.
Subsection (c): Minimal Risk to Subjects or Donors
Subsection (c) requires that the use of identifiable material "involves no more than minimal risk to the research subject or donor." This is a fundamental ethical safeguard ensuring that waivers are only granted when the research poses little to no risk of harm, whether physical, psychological, or social.
This provision aligns with international ethical standards, such as those articulated in the Declaration of Helsinki, which emphasize minimizing risk to participants. It protects individuals from potential adverse consequences arising from the use of their identifiable information without consent.
Subsection (d): Protection of Rights and Welfare
Subsection (d) mandates that the waiver "will not otherwise adversely affect the rights and welfare of the research subject or donor." This broad safeguard ensures that even if the previous conditions are met, the IRB must consider any other potential negative impacts on individuals' rights and well-being.
This clause exists to provide a holistic assessment of the waiver's implications, preventing harm that may not be immediately apparent through risk assessment alone. It reinforces the IRB's role as a protector of human dignity and autonomy.
Subsection (e): Contribution to the Greater Public Good
Finally, subsection (e) requires that the research "would reasonably be considered to contribute to the greater public good." This criterion ensures that waivers are granted only for research with significant societal benefits, justifying the ethical trade-offs involved in using identifiable information without consent.
This provision reflects the principle of beneficence in biomedical research ethics, emphasizing that the potential benefits to society must outweigh the risks and ethical concerns associated with waiving consent.
Why These Provisions Exist: Balancing Research Advancement and Ethical Protection
The HBRA's waiver provisions encapsulate a carefully calibrated balance between enabling important biomedical research and protecting individual rights. The use of individually-identifiable human biological material and health information is essential for many research projects, including those involving genetic studies, epidemiology, and personalized medicine.
However, such use raises significant ethical concerns, particularly regarding privacy, autonomy, and potential misuse of sensitive information. The conditions set out in Section 3 ensure that waivers are only granted when:
- The research cannot proceed without identifiable data;
- Obtaining consent is impractical;
- The risk to individuals is minimal;
- The rights and welfare of individuals are not compromised; and
- The research serves a significant public interest.
These safeguards collectively uphold the ethical principles of respect for persons, beneficence, and justice, which underpin human biomedical research regulation globally.
Conclusion
Section 3 of the Human Biomedical Research Act 2015 provides a robust framework for Institutional Review Boards to grant waivers for the use of individually-identifiable human biological material or health information. Each criterion within this provision serves a distinct and essential purpose in ensuring that such waivers are ethically justified and that the rights and welfare of research subjects and donors remain protected.
By requiring IRBs to carefully assess necessity, proportionality, risk, rights, and public benefit, the HBRA fosters an environment where valuable biomedical research can advance responsibly and ethically in Singapore.
Sections Covered in This Analysis
- Section 3, Human Biomedical Research Act 2015
Source Documents
For the authoritative text, consult SSO.